Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price hit a new 52-week high during mid-day trading on Friday . The company traded as high as $49.70 and last traded at $46.63, with a volume of 756709 shares changing hands. The stock had previously closed at $46.14.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Robert W. Baird increased their target price on shares of Definium Therapeutics from $37.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Needham & Company LLC boosted their price target on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Stifel Nicolaus raised their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $54.85.

Definium Therapeutics Price Performance

The business has a fifty day moving average of $37.45 and a 200-day moving average of $25.72. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. The firm has a market cap of $4.48 billion, a PE ratio of -18.04 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, research analysts predict that Definium Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Insider Activity

In other Definium Therapeutics news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the sale, the insider directly owned 320,571 shares in the company, valued at $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 48,096 shares of company stock valued at $2,165,763 over the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Scientech Research LLC bought a new stake in shares of Definium Therapeutics during the 3rd quarter valued at about $286,000. Mercer Global Advisors Inc. ADV grew its holdings in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after purchasing an additional 2,079 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Definium Therapeutics in the third quarter worth approximately $379,000. BNP Paribas Financial Markets increased its position in shares of Definium Therapeutics by 82.0% in the third quarter. BNP Paribas Financial Markets now owns 15,320 shares of the company’s stock worth $181,000 after purchasing an additional 6,903 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Definium Therapeutics by 43.6% in the third quarter. Blair William & Co. IL now owns 31,905 shares of the company’s stock worth $376,000 after purchasing an additional 9,687 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.